EDITORIAL SECTION

NextCure Inc Nasdaq NXTC NextCure and Avere Therapeutics Inc Avere a privatelyheld biotechnology company advancing oral therapies for IL driven inflammatory diseases

Ionis Pharmaceuticals Inc Nasdaq IONS today announced that its partner Biogen shared data from the Phase CELIA study evaluating diranersen an investigational antisense oligonucleotide ASO

The Alzheimers Drug Discovery Foundations ADDF Diagnostics Accelerator DxA and The Michael J Fox Foundation MJFF today announced a new million partnership to accelerate the development

PIERRE GUERIN an entity of Equans Process Solutions is a global provider specializing in the design manufacture and installation of vessels and automated process lines for the pharma biotech

ORIC Pharmaceuticals has initiated the global Himalayas Phase registrational trial to evaluate rinzimetostat in combination with NUBEQA darolutamide for patients with metastatic castrationresistant prostate cancer

Biogen has presented detailed Phase CELIA study results for its investigational antisense oligonucleotide ASO therapy diranersen at the Alzheimers Association International Conference AAIC

Atea Pharmaceuticals has initiated a firstinhuman Phase clinical trial of AT an investigational oral antiviral candidate being developed to treat hepatitis E virus HEV infection

Spero Therapeutics and Innovent Biologics have entered into an exclusive licensing agreement for SP IBI a Phase ready thirdgeneration Fcsilent antiCDL antibody for immunemediated diseases

BioMarin Pharmaceutical has announced that the US Food and Drug Administration FDA has accepted its supplemental New Drug Application sNDA seeking full approval of VOXZOGO vosoritide

The US Food and Drug Administration FDA has approved PADCEV enfortumab vedotinejfv in combination with Keytruda pembrolizumab or Keytruda QLEX pembrolizumab and berahyaluronidase